Replies to post #7556 on GTC Biotherapeutics (fka GTCB)

[DewDiligence]

I misread goseek’s question and thought he was asking about the rate of DVT in untreated patients with HD who undergo at-risk procedures.

To be clear: there should be no difference between ATryn and plasma-derived AT in efficacy at preventing DVT. This is ’s the reason the phase-3 trial was designed as a non-inferiority study.

[go seek]

it seems to me we should have a steady climb from here...

much of the risk has been taken out of the equation...
hoping for a bigger day tomorrow than most anticipate.

... a strong partnership and $2.50 - $3 soon thereafter.

of course no one can tell the future... but the picture is clearer as of 430p ET today